Product Description
For individuals with moderate to severe chronic plaque psoriasis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01010542)
Mechanisms of Action: IL22 Inhibitor
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Psoriasis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01010542 |
3226K1-1002 | P1 |
Terminated |
Psoriasis |
2011-05-20 |
2024-07-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT00822484 |
3226K2-1001 | P1 |
Completed |
Healthy Volunteers |
2009-09-01 |
2019-03-18 |
Treatments |
|
NCT00822835 |
3226K1-1000 | P1 |
Completed |
Healthy Volunteers |
2009-08-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|